Compare TLYS & RANI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TLYS | RANI |
|---|---|---|
| Founded | 1982 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Clothing/Shoe/Accessory Stores | Medicinal Chemicals and Botanical Products |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 128.1M | 106.9M |
| IPO Year | 2011 | 2021 |
| Metric | TLYS | RANI |
|---|---|---|
| Price | $3.94 | $0.67 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 4 |
| Target Price | $2.00 | ★ $7.50 |
| AVG Volume (30 Days) | 221.0K | ★ 635.8K |
| Earning Date | 06-03-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 62.34 | 57.14 |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $1,633,000.00 |
| Revenue This Year | $4.66 | $274.77 |
| Revenue Next Year | $1.74 | $79.44 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 58.85 |
| 52 Week Low | $1.14 | $0.42 |
| 52 Week High | $5.90 | $3.87 |
| Indicator | TLYS | RANI |
|---|---|---|
| Relative Strength Index (RSI) | 41.27 | 38.86 |
| Support Level | $3.68 | $0.61 |
| Resistance Level | $4.59 | $0.83 |
| Average True Range (ATR) | 0.31 | 0.05 |
| MACD | -0.02 | 0.00 |
| Stochastic Oscillator | 11.88 | 26.78 |
Tilly's Inc works as a specialty retailer of casual apparel, footwear, and accessories for young men, young women, boys, and girls. It offers an unparalleled selection of relevant brands, styles, colors, sizes, and price points. It delivers branded fashion and core styles for tops, outerwear, bottoms, and dresses. It also provides backpacks, hats, sunglasses, headphones, handbags, watches, and jewelry. It markets its products under the brand names of Vans, RVCA, Adidas, Nike SB, and Hurley, among others. It operates its stores in malls, lifestyle centers, power centers, community centers, outlet centers, street-front locations, and also through e-commerce.
Rani Therapeutics Holdings Inc is a clinical-stage biotherapeutics company advancing technologies to enable the development of orally administered biologics to provide patients, physicians, and healthcare systems with a convenient alternative to painful injections. The company has developed the RaniPill capsule, which is designed to deliver a wide variety of drug substances, including antibodies, proteins, peptides, and oligonucleotides. RaniPill is a proprietary and patented platform technology, intended to replace subcutaneous or IV injection of biologics with oral dosing. The company is also engaged in developing RaniPill HC, which is intended to enable the delivery of drug payloads in liquid form with high bioavailability.